Výsledky vyhledávání - "Rob H. Bradbury"

Potent and selective bivalent inhibitors of BET bromodomains

Publikováno v: Nature Chemical Biology. 12:1097-1104

Proteins of the bromodomain and extraterminal (BET) family, in particular bromodomain-containing protein 4 (BRD4), are of great interest as biological targets. BET proteins contain two separate bromodomains, and existing inhibitors bind to them monov

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2383592d971df225a15fa5861356ca2a
https://doi.org/10.1038/nchembio.2210

Zobrazit plný text záznamu

Abstract P5-09-20: Development of a novel selective estrogen receptor down-regulator which shows efficacy in pre-clinical models of endocrine resistance

Autor: Zena Wilson, Jon Curwen, Ermira Pazolli, Michael Hulse, N Reavey, Graeme Walker, Rachel Schiff, A.A. Rabow, Mandy Lawson, Rob H. Bradbury, Steve Powell, Agostina Nardone, Rachel Rowlinson, Celina M. D'Cruz, C. De Savi, Rowena Callis, Hazel M. Weir

Publikováno v: Cancer Research. 73:P5-09

With over 70% of breast cancers expressing the estrogen receptor alpha (ERa), treatment with either anti-hormonal therapies that directly block ER function (e.g.Tamoxifen) or therapies that block the production of estrogen itself (e.g. aromatase inhi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c923447479bae56bc973afe1a903e8b2
https://doi.org/10.1158/0008-5472.sabcs13-p5-09-20

Zobrazit plný text záznamu

Abstract 4744: Structure-based development of covalent inhibitors of the activating and T790M gatekeeper mutant forms of the epidermal growth factor receptor (EGFR) leading to the discovery of AZD9291

Autor: Nicola Colclough, Mark J. Anderton, Martine J. Mellor, Rob H. Bradbury, Heather L. McFarland, Richard A. Ward, Sam Butterworth, M Ray V. Finlay, Darren Cross, Pete G. Ballard, Michael J. Waring, Susan Ashton

Publikováno v: Cancer Research. 74:4744-4744

Small molecule inhibitors of the Epidermal Growth Factor Receptor (EGFR) tyrosine kinase such as gefitinib and erlotinib have been employed successfully in the treatment of non-small cell lung cancer (NSCLC) patients harboring an activating mutation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b497e25f1114f9701754b767510705fd
https://doi.org/10.1158/1538-7445.am2014-4744

Zobrazit plný text záznamu

Abstract B94: Discovery of and first disclosure of the clinical candidate AZD9291, a potent and selective third-generation EGFR inhibitor of both activating and T790M resistant mutations that spares the wild type form of the receptor

Autor: Heather L. McFarland, Peter Ballard, Claudio Chuaqui, Susan Ashton, M. Raymond V. Finlay, Sam Butterworth, Martine J. Mellor, Darren Cross, Nicola Colclough, Rob H. Bradbury, Richard A. Ward, Mark J. Anderton, Michael J. Waring

Publikováno v: Molecular Cancer Therapeutics. 12:B94-B94

Small molecule inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase such as gefitinib and erlotinib have been employed successfully in the treatment of non-small cell lung cancer (NSCLC) patients harboring an activating mutation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5bcabe801ac0cc9605b84173e10ac1bf
https://doi.org/10.1158/1535-7163.targ-13-b94

Zobrazit plný text záznamu

Abstract 3848: Preclinical profile of AZD3514: A small molecule-targeting androgen receptor function with a novel mechanism of action and the potential to treat castration-resistant prostate cancer

Autor: Craig N. Robson, Hayley Campbell, Sarah A. Loddick, Luke Gaughan, Dawn Trueman, A.A. Rabow, Sarah Ross, Natalie Stratton, Nigel Brooks, Stephen R. Wedge, Rob H. Bradbury, Daniel O'Neill, Elizabeth Mouchet, David Robinson, Fadhel Shaheen, Nicola Broadbent, Graeme Walker, Jim Growcott

Publikováno v: Cancer Research. 72:3848-3848

The androgen receptor (AR), an important molecular target in the aetiology and progression of prostate cancer, has been found recently to drive key signalling responses in castration resistant prostate cancer (CRPC) after classical androgen ablation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dd6fe3793f8f90b58be3a719e2fe94ec
https://doi.org/10.1158/1538-7445.am2012-3848

Zobrazit plný text záznamu

In vitro pharmacological profiles of kinase inhibitors: Comparison with other pharmaceuticals

Autor: Richard W. A. Luke, Rob H. Bradbury, Andrew Peter Thomas, Joanne Bowes, Mike Rolf, Neil James Hales, Andy Barker, Jean-Pierre Valentin, Edward Jolyon Griffen, Jason Grant Kettle

Publikováno v: Journal of Pharmacological and Toxicological Methods. 60:219

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d7f80c0d184ee73dcfeee0a39d9b5b8a
https://doi.org/10.1016/j.vascn.2009.04.052

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání